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Background: The most common causes of cholestatic jaundice are biliary atresia and idiopathic neonatal hepatitis
(INH). Specific disorders underlying INH, such as various infectious and metabolic causes, including neonatal
intrahepatic cholestasis caused by citrin deficiency (NICCD) especially, in East Asian populations are increasingly
being identified. Since most NICCD infants recovered from liver disease by 1 year of age, they often are
misdiagnosed with INH, leading to difficulty in determining the true prevalence of NICCD. Mutation(s) of human
SLC25A13 gene encoding a mitochondrial aspartate/glutamate carrier isoform 2 (AGC2), can lead to AGC2
deficiency, resulting in NICCD and an adult-onset fatal disease namely citrullinemia type II (CTLN2). To study the
prevalence of NICCD and SLC25A13 mutations in Thai infants, and to compare manifestations of NICCD and
non-NICCD, infants with idiopathic cholestatic jaundice or INH were enrolled. Clinical and biochemical data were
reviewed. Urine organic acid and plasma amino acids profiles were analyzed. PCR-sequencing of all 18 exons of
SLC25A13 and gap PCR for the mutations IVS16ins3kb and Ex16+74_IVS17-32del516 were performed. mRNA were
analyzed in selected cases with possible splicing error.
Results: Five out of 39 (12.8%) unrelated infants enrolled in the study were found to have NICCD, of which three
had homozygous 851del4 (GTATdel) and two compound heterozygous 851del4/IVS16ins3kb and 851del4/
1638ins23, respectively. Two missense mutations (p.M1? and p.R605Q) of unknown functional significance were
identified. At the initial presentation, NICCD patients had higher levels of alkaline phosphatase (ALP) and
alpha-fetoprotein (AFP) and lower level of alanine aminotransferase (ALT) than those in non-NICCD patients
(p< 0.05). NICCD patients showed higher citrulline level and threonine/serine ratio than non-NICCD infants
(p< 0.05). Fatty liver was found in 2 NICCD patients. Jaundice resolved in all NICCD and in 87.5% of non-NICCD
infants at the median age of 9.5 and 4.0 months, respectively.
Conclusion: NICCD should be considered in infants with idiopathic cholestasis. The preliminary estimated
prevalence of NICCD was calculated to be 1/48,228 with carrier rate of 1/110 among Thai infants. However, this
number may be underestimated and required further analysis with mutation screening in larger control population
to establish the true prevalence of NICCD and AGC2 deficiency.
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Cholestatic jaundice affects approximately 1 in every
2,500 infants world-wide [1,2]. The most common
causes are biliary atresia and idiopathic neonatal hepa-
titis (INH). An increase in specific disorders underlying
INH are being identified, which include various infec-
tious and metabolic causes such as tyrosinemia, alpha-1
antitrypsin deficiency, and galactosemia [3]. INH could
be caused by unidentified metabolic disorders.
Deficiency of AGC2, liver-type mitochondrial aspartate-
glutamate carrier (AGC) [4], is an autosomal recessive dis-
order caused by mutations of the SLC25A13 gene (7q21.3)
[5]. It results in two distinct phenotypes: adult-onset type II
citrullinemia (CTLN2; OMIM 603471), and neonatal intra-
hepatic cholestasis caused by AGC2 deficiency (NICCD;
OMIM 605814) [6]. CTLN2 is characterized by recurrent
episodes of altered mental status, hyperammonemia and
coma which can occur at any age but usually in adult-
hood [5,7,8]. NICCD patients present in the first few
months of life with milder symptoms characterized by
intrahepatic cholestasis, diffuse fatty liver, parenchymal cel-
lular infiltration associated with hepatic fibrosis, hypoalbu-
minemia, coagulopathy, liver dysfunction with or without
hypoglycemia, galactosuria, multiple aminoacidemia includ-
ing elevated citrulline, arginine, threonine, methionine,
phenylalanine, and tyrosine concentrations [8-12].
NICCD was first described by Ohura et al. in 2001
[13]. Increasing numbers of NICCD patients have been
reported with the majority from Japanese and East Asian
populations, including Taiwanese [14,15], Korean [16]
and Chinese [12,17]. A handful of patients with NICCD
have been identified in Arabic, Pakistani, Caucasian des-
cendants, suggesting a panethnic disease [16,18-20].
Since most NICCD infants recovered from liver disease
by 1 year of age, they often are misdiagnosed with INH,
leading to difficulty in determining the true prevalence
of NICCD [10]. Because clinical manifestations and bio-
chemical findings are nonspecific for NICCD, DNA ana-
lysis or Western blot analysis of AGC2 protein in
lymphocytes is the most reliable diagnostic tool [21].Figure 1 Agraose gel electrophoresis showing IVS16ins3kb (XIX), Mut
fragment representing the IVS16ins3kb (XIX) and the 990bp fragment repre
restriction digest. The 851del4 mutation abolishes the restriction site, wher
2.5% gel showing 109bp-product of PCR using primers E1F/E1_1MT-R. The
20bp-fragments.The objectives were to study the prevalence of NICCD
in Thai infants with idiopathic cholestasis, mutation
spectrum of SLC25A13 in Thai NICCD, and comparison
of clinical manifestations and blood chemistry between
NICCD and non-NICCD infants.Results
Thirty-nine unrelated infants with idiopathic cholestasis
or INH participated in the study, 18 from cohort-A (12
males and 6 females) and 21 from cohort-B (17 males and
4 females), making a male/female ratio 3:1. Median age at
onset of the jaundice was 1 month (range 0.5-5.0) in both
cohorts. The median age at enrollment was 60.5 months
(range 12.0-131.0) in cohort-A, and 3.0 months (range
1.0-16.0) in cohort-B. At the time of enrollment, in
cohort-A, jaundice was resolved in all but one patient,
whereas all patients in cohort-B presented with jaundice.
Five male patients (1 from cohort-A and 4 from cohort-B)
were confirmed to have NICCD.Mutation data
Genotypes in the NICCD cases were homozygous
851del4 or GTATdel (mutation [I]) in Patients 1, 2, and
5, 851del4/IVS16ins3kb (or mutation [XIX]) in Patient 3
(Figure 1A), and 851del4/c.1638-1660dup (or mutation
[III]: 1638ins23) in Patient 4. There were two suspected
NICCD cases with genotype p.M1?/wt in Patient 6 and
R605Q/wt in Patient 7 (both from cohort-A). None of
the patients had mutation [XX] (or Ex16+74_IVS17-
32del516). Two reported single nucleotide polymorph-
isms (SNPs) including IVS4+6A>G (rs6957975) and
L398L (rs2301629); and 2 newly identified SNPs, IVS4-
52 A>G and IVS17-12C>A were discovered (Table 1).
After an identification of 851del4 in Patients 1-5, we
established a screening method using PCR with primer
SLC25A13_E9 forward and reverse (for all primers, see
Additional file 1) followed by HpyCH4IV (A0CGT) re-
striction digestion (Figure 1B). This test was used for
simple and rapid screening of the 851del4 in the controlations 851del4 (I), and p.M1? variant. A: 1.5% gel revealing 3.65 kb
senting normal allele.; B: 1.5% gel showing exon 9-PCR-HpyCH4IV
eas the normal allele was cut, yielding 179 and 122bp fragments.; C:
p.M1? allele produces an EagI restriction site, yielding 89 and










Exon 1 2T>C NA p.M1? unknown 1/39 (het: Pt-6) (0.013) 3/100 (0.015) present study
Intron 4 IVS4+6A>G NA none benign AA 17/39; AG 18/39;
GG 4/39 (AF: A 0.67; G 0.33
NA rs6957975;
ss28503034
Intron 4 IVS4-52 A>G NA none benign 1/39 (het: Pt-8) (0.013) NA present study
Exon 9 c.851delGTAT I p.M285fsX286 pathogenic 5/39 (hom: Pt-1,2,5 and
het: Pt-3,4) (0.103)
0/100 Kobayashi 1999 [5]
Exon 12 c.1194A>G NA p.L398L benign AA 9/39; AG 12/39;
GG 18/39 (AF:A 0.385; G 0.615)
NA rs2301629
Exon 17 c.1814G>A NA p.R605Q unknown 1/39 (het: Pt-7) (0.013) 0/100 present study
Exon 16 c.1638-1660dup
(1638ins23)
III p.A554fsX570 pathogenic 1/39 (het: Pt-4) (0.013) 0/100 Kobayashi 1999 [5]
Intron 16 IVS16ins3kb XIX p.A584fsX585 pathogenic 1/39 (het: Pt-3) (0.013) 0/100 Tabata 2008 [20]
Intron 17 IVS17-12 C>A NA none benign 1/39 (het: Pt-9) (0.013) NA present study
AF allele frequency, Cholestatic infants, idiopathic infantile cholestasis individuals, hom homozygous, het heterozygous, NA not applicable/available, Pt patient.
GenBank reference sequences were NT_079595 and NM_014251.2.
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the deletion in the patients.
The p.M1? variant does not alter restriction site, there-
fore, a reverse primer E1_M1T-R was designed and used
with forward primer E1-F to yield PCR product containing
the mutated site and to create an artificial EagI restriction
site (C0GGCCG) in the p.M1? allele (Figure 1C). This test
was used to screen the 100 controls.
Sequencing of cDNA from an 851del4-homozygous pa-
tient and the p.R605Q-heterozygous individual revealed
correct splicing of the exons involved (data not shown).
None of the controls were found to have 851del4,
IVS16ins3kb, 1638ins23, and the p.R605Q variant (creat-
ing a BsrDI restriction site). The p.M1? was present in
only heterozygous state in 3 controls (Table 1).
Comparison of clinical and laboratory findings between
NICCD and non-NICCD infants
The major presentations of five definite NICCD patients
(Patients 1-5) were cholestatic jaundice and hepatomeg-
aly. Median age at onset of cholestatic jaundice was 0.5
months (range 0.1-4.0) in NICCD patients and 1.0
month (range 0.5-5.0) in non-NICCD patients (Patients
8-39). Splenomegaly was initially found in 2 NICCD
(40%) and 11 non-NICCD patients (34.4%). At presenta-
tion, NICCD patients had significantly higher alkaline
phosphatase (ALP), lower ALT and higher alpha-
fetoprotein (AFP) than in non-NICCD infants (Table 2).
Coagulopathy, galactosuria and hypoglycemia were re-
markably observed among NICCD patients but not in
the non-NICCD infants. Serum AFP levels were not
available in suspected NICCD cases. Plasma amino acid
(PAA) profiles were only available from four NICCD
patients (from cohort-B) and 18 non-NICCD patientswhich showed elevated citrulline and elevated threonine/
serine ratio in NICCD patients compared to those in
non-NICCD patients (p<0.05) (Table 3).
Liver histology was available in 3 NICCD and 15 non-
NICCD infants. Cholestasis and fatty changes were found
in two NICCD patients (Patients 3 and 4). In addition,
histologic features of cirrhosis were demonstrated in Pa-
tient-4. Patient-2 had marked cellular swelling, disarray of
hepatic cords, cholestasis, multinucleated giant cell trans-
formation, and decreased interlobular bile ducts. The
major histological findings in non-NICCD infants were
multinucleated giant cell transformation and features
compatible with INH (n=9), paucity of interlobular bile
duct (n=4), fatty changes (n=1; Patient 10) and severe peri-
portal fibrosis (n=1). The liver histologic findings of the 2
suspected NICCD patients were compatible with INH.
The management of all the patients was directed to-
ward treating the consequence of cholestasis, consisting
of non-lactose and medium chain triglycerides formula
and supplementation with fat-soluble vitamins. Jaundice
resolved in all NICCD patients at the median age of 6.6
months (range 5-11) and liver biochemistry became nor-
mal in 4/5 NICCD patients (except patient 4) at the me-
dian age of 9.5 months (range 5-10). Patient 4 had the
most severe manifestation in the NICCD group in this
study. He had jaundice started at 1 month old, develop-
mental delay due to unrecognized hypoglycemia till the
age of 8 months when he was referred to our depart-
ment. After 4 months of treatment, jaundice and
hypoglycemia resolved and liver chemistry became near
normal. At the time of this report, he is 38 month-old
with appropriate growth and psychomotor development.
Jaundice resolved in the two suspected NICCD cases,
at the age of 5 and 9 months, respectively. Among the
Table 2 Liver functions and laboratory data at the first presentation of definite NICCD, and non-NICCD patients







TB (mg/dL) 7.1 (4.7-9.8) 7.6 (3.5-49.9) 0.2-1.0 0.61
DB (mg/dL) 3.8 (2.6-6.9) 5.9 (1.8-40.1) 0.0-0.7 0.18
ALP (U/L) 1016 (665-3014) 540 (256-1935) 185-555 0.01
GGT (U/L) 160 (127-289) 188 (35-936) 12-123b 0.86
AST (U/L) 144 (62-268) 173 (63-942) 15-37 0.48
ALT (U/L) 61 (49-127) 135 (28-525) 30-65 0.03
AST/ALT ratio 2.1 (1.1-3.3) 1.3 (0.6-5.2) - 0.07
TP (g/L) 51 (38-61) 54 (34-75) 64-82 0.42
Albumin (g/L) 33 (25-37) 35 (17-38) 34-50 0.33
AFP (ng/mL) 60500 (38930 – 60500) (n=4) 22678 (30-60500) (n=9) 88±87c 0.01
Hypoglycemiad 2 (40%) 1 (3.1%) - 0.01
Galactosuria 3/4 (75%) 0 -
Prolonged PTe 2/3 (67%) 6/24 (25%) - 0.14
TB total bilirubin, DB direct bilirubin, ALP alkaline phosphatase, GGT γ-glutamyltransferase, AST aspartate aminotransferase, ALT alanine aminotransferase, TP total
protein, AFP alpha-fetoprotein, PT prothrombin time, NA not available.
a Only definite NICCD and non-NICCC groups were compared, and statistical significance if P-value <0.05.
b Normal values for children 1-2 months, 12-123; 2-4 months, 8-90; 4 months-10 years, 5-32 U/L.
c Normal values for children at 3 months, 88±87; 5 months, 46.5±19; 6 months, 12.5±9.8; 8-12 months, 8.5±5.5 ng/mL.
d Hypoglycemia defined as blood glucose <2.5 mmol/L or 45 mg/dL.
e Prolonged PT defined as INR>1.2.
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at median age of 4 months (range 2-24). The remainder
had progressive jaundice leading to cirrhosis; one patient
underwent liver transplantation and has been well, and
another patient died of complications of end-staged liver
disease.
Discussion
In the present study, the 851del4 was accounting for
80% of the mutant alleles identified. We demonstrate
12.8% (5/39) prevalence of NICCD among Thai infants
with idiopathic cholestatic jaundice/INH. Ko et al and
Fu et al reported 6% (3/47) and 9.5% (38/400) prevalence





Citrulline (umol/L) 60 (36-152)
Methionine (umol/L) 141 (32-243)
Phenylalanine (umol/L) 38 (26-40)
Threonine (umol/L) 181 (139-326) 1
Arginine (umol/L) 63 (50-135)
Tyrosine (umol/L) 121 (33-166)
Threonine/serine ratioa 1.63 (1.37-2.10) 1
Fisher ratio (BCAA/AAA) 1.12 (0.67-2.47) 2
BCAA branched chain amino acids (valine + isoleucine + leucine), AAA aromatic am
a median and 25-75% range of threonine/serine ratio in NICCD 2.29 (1.69-2.81) were
b Only definite NICCD and non-NICCC groups were compared, and statistical signifiidiopathic cholestasis, respectively [22,23]. By employing
the above prevalence of 12.8%, 40% of Thai infantile
cholestatsis being have idiopathic cholestasis [24] (and
our unpublished data), and panethnic incidence of cho-
lestatic jaundice 1/2,500 infants (no specific data for
Thai infants) [1,2], the incidence of NICCD among Thai
infants is calculated to be 1 in 48,828. By reverse calcula-
tion based on Hardy-Weinberg equation, the frequency
of SLC25A13 mutation-carrier among Thai infants cal-
culated from the incidence of NICCD is predicted to be
1 in 110 (q2=1/48,828; 2pq = 2x≅1x1/220). This number
is lower than the frequency of SLC25A13 mutations car-
rier among Chinese (1/63), Japanese (1/65), and Korean




17 (8-42) 3-35 0.004
37 (11-702) 9-42 0.23
45 (11-291) 31-75 0.19
40 (42-339) 24-174 0.11
41 (12-92) 12-133 0.16
74 (18-557) 22-108 0.49
.16 (0.56-2.30) 1.10 (0.88-1.19) 0.03
.23 (0.01-3.42) 3.42±0.33 0.13
ino acids (phenylalanine + tyrosine).
as described by Kobayashi K and Saheki T (GeneReviews) [8].
cance if P-value <0.05.
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study because not all infants with SLC25A13 mutation(s)
on both alleles manifest NICCD symptoms and that the
carrier rates described in those East Asian populations
were obtained through molecular genetic screening of
control population which is more reliable method to
provide epidemiologic data.
If p.M1? is considered pathologic allele and its carrier
rate (3/100) by population analysis is taken into account
with the carrier rate of the three mutations (851del4,
IVS16ins3kb, and 1638ins23) obtained from the cho-
lestatic infants group, it makes a carrier rate of 1 in 52
(4/210), giving a new estimated incidence of NICCD 1 in
11,025. Given no available data of p.M1? in other popu-
lation to compare and the absence of functional prove of
the p.M1?, it may be too premature to include the car-
rier rate of p.M1? for estimation of the incidence of
NICCD in Thai population.
We tried to compare the genotype of the most severe
case (Patient 4) in the present study to those severe
NICCD cases published in the literature. Only four
NICCD patients have been reported to have progressive
liver disease requiring liver transplantation [9,26-28].
Genotypes of those cases were 851del4/IVS11+1G>A
[9,27], 1638ins23/S225X [26], and genotype not specified
in two cases; therefore, genotype-phenotype association
could not be concluded.
Among over 50 mutations of SLC25A13 described [25],
the 851del4 (mutation I) and IVS11+1G>A (mutation II)
are the most frequent mutations described among Japa-
nese affected population, accounting for 70% of the mu-
tant alleles, and 851del4 is the most frequent in Chinese
[8,20]. The other common mutations were 1638ins23,
S255X, and IVS6+5G>A [20]. There is no doubt about the
pathogenicity of the mutations 851del4, IVS16ins3kb, and
c.1638-1660dup because these mutations have been iden-
tified multiple times in East Asian affected population al-
though, functional data is quite limited.
The pathogenicity of the novel p.M1? variant is uncer-
tain. With the absence of the original initiation start
codon, the first AUG codon is located at nt 71-73 lead-
ing to translation of a non functional short polypeptide
of 21 amino acids and possible degradation of the mu-
tant mRNA through a nonsense-mediated mRNA decay
mechanism [29]. Whether or not this particular allele
has deleterious effect on AGC2 function, it remains to
be elucidated. The p.R605Q mutation occurs at a con-
served amino acid position of SLC25A13 (AGC2) and
SLC25A12 (aralar) across various species (AGC2: cow,
chicken, mouse, rat, chimpanzee, horse; aralar: human,
monkey, macaque, dog, mouse); although possibly be
deleterious, its pathogenicity remains to be proven.
When comparing with the non-NICCD cases, the
NICCD patients had significantly higher ALP and lowerALT levels, higher citrulline concentration and threo-
nine/serine ratio, supporting previous studies [9,11,30].
The AST/ALT ratio seemed higher in NICCD group,
but was not statistically significant. Failure to thrive was
a presenting feature in 37-50% of NICCD patients, but
not found in our cohort [11,12]. NICCD cannot be
excluded on the basis of normal PAA profiles, as evi-
denced in Patients-3. Liver histology was not always
diagnostic for NICCD. The characteristic histology of
NICCD including cholestatsis and fatty change
[10,11,31,32] was found in two cases in this study. Bile
duct paucity, an uncommon finding in NICCD which
has been demonstrated in one report [31] was found in
one patient (Patient 2). His clinical manifestations were
moderately severe with cholestatic jaundice, coagulopa-
thy, galactosuria and jaundice resolved at 6 months of
age. Fatty liver was found in a non-NICCD patient (Pa-
tient 10) who had jaundice since 1 month and the jaun-
dice resolved by 3 months without identified other
metabolic liver diseases. Another non-NICCD case, Pa-
tient 11, had markedly high ALP and AFP (1935 and
>60,500 respectively, shown in Table 2). Her jaundice
started at 1 month and resolved at 6 months of age, and
her liver histology was the feature of INH. Of note,
Patients 10 and Patient 11 could have NICCD but with
unidentifiable mutation(s).
There were limitations of the present study. Firstly,
using the panethnic incidence of infantile cholestasis for
the estimation of the prevalence of NICCD among Thai
infants raises concern on the precision of the predicted
prevalence. It would be more reliable to use prevalence
of infantile cholestasis among Thai population; however,
such data does not exist. Secondly, the prevalence of
NICCD obtained by calculation from manifesting infants
may be underestimated because AGC2 deficiency is a
disease with incomplete penetrance. Thirdly, large dele-
tion and/or insertion could be missed by PCR-direct se-
quencing. Fourthly, the lack of functional analysis to
support the pathologic significance of novel SLC25A13
variants identified in the present study leads to inconclu-
sive data of some patients (Patients 6 and 7). Existing
system for functional analysis of AGC2 protein is com-
plicated and difficult to conduct [33]. New method of
functional analyses of AGC2 mutation is needed to pro-
vide more insight into SLC25A13 variants.
Conclusion
NICCD has been underestimated and should be consid-
ered in infants with idiopathic cholestatic jaundice, espe-
cially when associated with markedly high ALP and AFP,
fatty liver and elevated plasma citrulline. It is impossible
to establish the true incidence of NICCD and AGC2 de-
ficiency among Thai infants by the method used in the
present study. Molecular genetic analysis of general
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association with the variants is required to answer that
question. Development of alternative and simple system
for functional testing for AGC2 variants is necessary for
better understanding pathogenic mechanism of AGC2
genetic variants, especially for those newly identified.
Material and methods
Patients and clinical analysis
Infants with idiopathic cholestasis or idiopathic neonatal
hepatitis were recruited. Those diagnosed during January
1996 - September 2006 were assigned to cohort-A
(retrospective cohort), and those diagnosed during Octo-
ber 2006 - February 2010 to cohort-B (prospective co-
hort). Idiopathic cholestasis was defined as serum total
bilirubin (TB) exceeding 5 mg/dL and direct bilirubin
(DB) level > 20% of TB or DB > 1 mg/dL if TB was < 5
mg/dL, and without an identifiable cause. Written
informed consents were obtained from each parent, fol-
lowing the approval of Ramathibodi Institutional Review
Board. Clinical data were reviewed. Routine investiga-
tions for infantile cholestasis included viral studies, ab-
dominal ultrasonography, hepatobiliary scintigraphy and
metabolic screening (urine reducing substance). Biliary
atresia and extrahepatic obstruction were excluded in all
cases. Liver biopsy was performed if the diagnosis
remained inconclusive. Urine organic acids and plasma
amino acid (PAA) were analyzed in the patients from
cohort-A who still had jaundice at the time of enroll-
ment, and all patients from cohort-B. Fischer and threo-
nine/serine ratio were calculated (Fischer ratio =
branched-chain amino acids valine + leucine + isoleu-
cine/aromatic amino acids tyrosine + phenylalanine).
Specific investigations for progressive familial intrahepa-
tic cholestasis (PFIC), Alagille syndrome and specific
metabolic liver diseases were performed in selected
cases. Investigations for alpha-1 antitrypsin deficiency
were not routinely performed since a previous study
showed that this disorder is unlikely to be a cause of
liver diseases among Thai children [34].
Genetic analysis
Genomic DNA (gDNA) was prepared from peripheral
blood lymphocytes by phenol-chloroform extraction.
PRIMER 3 was used for primer design (http://www.
Frodo.wi.mit.edu/cgi-bin/primer3). GenBank reference
sequences were NT_079595 and NM_014251.2 (AGC2
isoform 2). Sequencing was performed on an ABI 3100
DNA sequencer after purification with QIAquick PCR
purification kits (QAIGEN®; California, USA). Long-
range PCR was performed according to the manufac-
turer’s instructions (Long PCR Enzyme Mix; Fermentas
Life Sciences, California, USA). mRNA transcripts were
isolated from peripheral blood with the QIAamp RNABlood Mini Kit (QIAGENTM), then reverse transcribed
into single-stranded complementary DNA (cDNA) using
Superscript III Reverse Transcriptase (Invitrogen). Pri-
mer sequences for gDNA and cDNA amplification are
available as supplementary data at the journal website.
PCR-sequencing of all 18 exons of the SLC25A13 gene
of genomic DNA from all the infants and of cDNA from
selected cases was performed. To detect both 3kb inser-
tion of intron 16 (mutation [XIX] or IVS16ins3kb) and
516bp deletion of exon 16 connecting intron 17 ([XX]
or Ex16+74_IVS17-32del516), gap PCR was performed
by using long-range PCR and primers Ex16F and Ex18-
30R, as previously described [20]. Positive controls for
the insertion were kindly provided by Prof. Kobayashi
from Kagoshima University. Once a mutation(s) was
identified, genetic analysis of family members was per-
formed and PCR-restriction digest with appropriate
endonuclease restriction enzymes was carried out in 100
healthy controls (regular blood donors). The IVS16ins3kb
was also screened in the 100 controls. cDNA analysis was
performed in selected case with possible splicing error.
Primer sequences and detailed molecular method are
available as an Additional file 1. Nomenclature of
newly identified SLC25A13 variants is assigned following
the guidelines of the Human Genome Variation Society
(http://www.hgvs.org/mutnomen) [35].
Infants with pathogenic SLC25A13 mutation(s) identi-
fied on both alleles were considered definite case of
NICCD while those with pathogenic/unclear significant
mutation identified on only one allele were considered
suspected NICCD, and those known as nonpathogenic/
silent or unidentifiable mutation were considered non-
NICCD cases.Statistical analysis
Data were analyzed using SPSS (version 13.0, SPSS Inc,
Chicago, Illinois, USA). Mann–Whitney U test and Fisher's
Exact test were used to compare continuous variables and
dichotomous variables, respectively. A P-value of <0.05 was
considered statistically significant.Additional file
Additional file 1: Primer sequence and molecular method.Competing interests
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